Bio-Techne

Bio-Techne Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Bio-Techne (TECH) as of Oct 9, 2026 is 171.76. In the previous year, Cash Conversion Cycle (CCC) was 201.44 — a change of -14.74% (lower).

Cash Conversion Cycle

171.76

YoY

-14.74%

Last updated:

Cash Conversion Cycle (CCC) of Bio-Techne is 2026 171.76 . Cash Conversion Cycle (CCC) of Bio-Techne was 2025 201.44 . It decreases by -14.74% lower compared to the previous year.

The Bio-Techne Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
183.87 USD
Jan 1, 2020
174.90 USD
Jan 1, 2021
163.94 USD
Jan 1, 2022
176.35 USD
Jan 1, 2023
215.37 USD
Jan 1, 2024
208.92 USD
Jan 1, 2025
201.44 USD
Jan 1, 2026
171.76 USD
The Bio-Techne Cash Conversion Cycle history
YEARCash Conversion CycleYoY
171.76-14.74%
201.44-3.58%
208.92-2.99%
215.37+22.12%
176.35+7.57%
163.94-6.27%
174.90-4.87%
183.87+72.62%
106.52-33.25%
159.57+6.20%
150.25+1.89%
147.47-1.07%
149.07—
Access this data via the Eulerpool API

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Techne stock

Cash Conversion Cycle (CCC) of Bio-Techne is 171.76 in 2026.

Cash Conversion Cycle (CCC) of Bio-Techne changed from 201.44 to 171.76, representing a -14.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Bio-Techne with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — Bio-Techne

All Key Metrics — Bio-Techne